Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repisalud
Publication Reseña (Review)

Clonal haematopoiesis of indeterminate potential: an emerging risk factor for type 2 diabetes and related complications.

  • Zuriaga, María A
  • Fuster, José J
The accumulation of acquired somatic mutations is a natural consequence of ageing, but the pathophysiological implications of these mutations beyond cancer are only beginning to be understood. Most somatic mutations are functionally neutral, but a few may confer a competitive advantage to a stem cell, driving its clonal expansion. When such a mutation arises in haematopoietic stem cells, it leads to clonal haematopoiesis, in which a significant proportion of blood cells originate from the mutant stem cell and share the same mutation. Clonal haematopoiesis of indeterminate potential (CHIP), a specific subset of clonal haematopoiesis driven by myeloid leukaemia-related somatic mutations, has been linked to a higher risk of various age-related conditions, particularly CVD, by exacerbating inflammatory responses. Emerging evidence suggests that CHIP may also contribute to the pathogenesis of type 2 diabetes and some of its complications. This review synthesises current knowledge on CHIP and its potential as a novel risk factor for type 2 diabetes, highlighting the need for further research to clarify this relationship and to explore its potential value in developing personalised preventive care strategies for type 2 diabetes and related conditions.
Repisalud
Publication Artículo científico (JournalArticle)

The emerging role of clonal haematopoiesis in the pathogenesis of dilated cardiomyopathy.

  • Verdonschot, Job A J
  • Fuster, Jose J
  • Walsh, Kenneth
  • Heymans, Stephane R B
The increased sensitivity of novel DNA sequencing techniques has made it possible to identify somatic mutations in small circulating clones of haematopoietic stem cells. When the mutation affects a 'driver' gene, the mutant clone gains a competitive advantage and has the potential to expand over time, a phenomenon referred to as clonal haematopoiesis (CH), which is emerging as a new risk factor for various non-haematological conditions, most notably cardiovascular disease (e.g. heart failure). Dilated cardiomyopathy (DCM) is a form of non-ischaemic heart failure that is characterized by a heterogeneous aetiology. The first evidence is arising that CH plays an important role in the disease course in patients with DCM, and a strong association of CH with multiple aetiologies of DCM has been described (e.g. inflammation, chemotherapy, and atrial fibrillation). The myocardial inflammation induced by CH may be an important trigger for DCM development for an already susceptible heart, e.g. in the presence of genetic variants, environmental triggers, and comorbidities. Studies investigating the role of CH in the pathogenesis of DCM are expected to increase rapidly. To move the field forward, it will be important to report the methodology and results in a standardized manner, so results can be combined and compared. The accurate measurement of CH in patients with DCM can provide guidance of specific (anti-inflammatory) therapies, as mutations in the CH driver genes prime the inflammasome pathway.
Repisalud
Publication Artículo científico (JournalArticle)

A high-fat diet nutritional intervention reprograms cardiac metabolism and improves systolic function in a pig model of heart failure with reduced ejection fraction.

  • Galán-Arriola, Carlos
  • Pérez-Camargo, Daniel
  • Ferrarini, Alessia
  • Mastrangelo, Annalaura
  • Higuero-Verdejo, María Isabel
  • López-Martín, Gonzalo Javier
  • Devesa, Ana
  • Gutiérrez, Rocío Villena
  • Fernández-Tocino, Miguel
  • Díaz-Guerra, Anabel
  • Montero-Cruces, Lourdes
  • Carnero, Manuel
  • Fernández-Jiménez, Rodrigo
  • Fuster, Valentin
  • Sánchez-González, Javier
  • Ibáñez, Borja
Most forms of heart failure are characterized by a metabolic switch from the use of fatty acids to glucose as the main fuel source for ATP generation in the myocardium. Whether metabolic reprogramming is a therapeutic target remains controversial. In this study, heart failure with reduced ejection fraction (HFrEF) and metabolic switch (i.e., increased myocardial glucose uptake) was induced in pigs by generating viable dysfunctional myocardium secondary to progressive coronary artery stenosis. Pigs (n = 19) were then randomized to a high-fat diet (HFD, chow diet supplemented with 20% lard) or control diet (no supplementation) for two months. Pre- and post-nutritional treatment contrast-enhanced cardiac magnetic resonance (CMR) and FDG-PET/CT studies were performed. Hearts were then harvested for further analysis. LVEF significantly improved in pigs receiving the 2-month HFD (38% [33, 43] to 54% [47, 62], p = 0.036) but remained unchanged in control-diet pigs (36% [35, 45] to 41% [38, 43], p = 0.24). HFD-fed pigs had a smaller extent of fibrosis after the dietary intervention (late gadolinium enhancement 0.45% LV [0.17, 1.67] vs 6.23 [5.54, 9.57], p = 0.0047). On FDG-PET, a reversion of the metabolic reprogramming in the LAD-dysfunctional myocardium was observed only in HFD-fed pigs (0.46 counts [0.21, 0.65] vs 1.80 [1.53, 2.83], p = 0.016). Transmission electron microscopy of explanted hearts revealed less fragmented mitochondrial and a lower lipid droplet density in cardiomyocytes from HFD-fed pigs (38 per 10 µm3 [34, 50] vs 96 [78, 124], p = 0.022), and this was accompanied by increased expression of genes involved in fatty acid metabolism and downregulation of genes encoding glucose import proteins. In conclusion, in a large animal model of HFrEF secondary to myocardial dysfunction with a metabolic switch, a nutritional intervention based on HFD feeding was associated with a cardiac metabolic restoration of fatty acid substrate use, restoration of cardiomyocyte lipid trafficking and significantly improved systolic function.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Acyl-CoA-binding protein as a driver of pathological aging

  • Montégut, Léa
  • Lambertucci, Flavia
  • Moledo-Nodar, Lucas
  • Fiuza-Lucesd, Carmen
  • Rodríguez-López, Carlos
  • Serra-Rexach, Jose Antonio
  • Lachkar, Sylvie
  • Motiño, Omar
  • Abdellatif, Mahmoud
  • Duranda, Sylvère
  • Aprahamian, Fanny
  • Carbonnier, Vincent
  • Corre, Delphine Le
  • Mouillet-Richardk, Sophie
  • Chen, Hui
  • Sauvat, Allan
  • Dong, Yanbing
  • Li, Sijing
  • Rong, Yan
  • Pietrocola, Federico
  • Laurent-Puig, Pierre
  • López-Otín, Carlos
  • Martinsa, Isabelle
  • Barcena, Clea
  • Lucia, Alejandro
  • Kroemer, Guido
The tissue hormone acyl coenzyme A–binding protein (ACBP, encoded by the gene diazepam-binding inhibitor, DBI) has been implicated in various facets of pathological aging. Here, we show that ACBP plasma concentrations are elevated in (close-to-)centenarians (mean ± SD age 99.5 ± 4.5 y) commensurate with their health deterioration, correlating with a reduced glomerular filtration rate and a surge in senescence-associated cytokines. ACBP neutralization by means of a monoclonal antibody (mAb) improved health span in a strain of progeroid mice. In a mouse model of chronic kidney injury induced by cisplatin, anti-ACBP mAb administration counteracted both histopathological and functional signs of organ failure. ACBP inhibition also prevented the senescence of tubular epithelial cells and glomerular podocytes induced by cisplatin or doxorubicin, respectively, as measurable by the immunohistochemical detection of cyclin-dependent kinase inhibitor 1A (CDKN1A, best known as p21). Senescence was also prevented by anti-ACBP mAb treatment in additional mouse models of accelerated aging. This applied to liver damage induced by a combination of high-fat diet and carbon tetrachloride, where hepatic cells become senescent. Moreover, administration of anti-ACBP mAb prevented natural and doxorubicin-accelerated cardiomyocyte senescence. We performed single-nucleus RNA sequencing to study the transcriptome of hearts that had been exposed to doxorubicin and/or anti-ACBP in vivo. In cardiomyocytes, doxorubicin caused an anti-ACBP-reversible dysregulation of mRNAs coding for cardioprotective proteins involved in autophagy, fatty acid oxidation, mitochondrial homeostasis, and oxidative phosphorylation. Altogether, these findings plead in favor of a broad age-promoting effect of ACBP across different organ systems., We also thank Agustín Brea Pastor from the University of Oviedo for his help with the computer tomographic imaging process. G.K. receives grants by the Ligue contre le Cancer (équipes labellisées); Institut National du Cancer (INCa); European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410), Prevalung (Grant agreement number 101095604), Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen); INCa; Agence Nationale de la Recherche (ANR), i.e., French Ministry of Health PIA5, ANR, program RHU5 “ANR-21-RHUS-0017” IMMUNOLIFE and ANR-23-RHUS-0010 LUCA-pi; Seerave Foundation, an European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444; project acronym: ICD-Cancer) and Site de reserche intégrée sur le cancer (SIRIC) Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by INCa, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001. L.M-N. is supported by the FPI program (PRE2021-100065) funded by MCIN/ AEI /10.13039/501100011033. C.B. is supported by the Ramon y Cajal program (RYC2021-031291-I) funded by MICIN/AEI/10.13039/50100011033 and cofunded by European Union NextGenerationEU/PRTR. C.R-L is supported by the Biomedical Research Networking Centre on Frailty and Healthy Aging (CIBERFES, CB16/10/00314). Research by C.F.L. is funded by Instituto de Salud Carlos III (ISCIII) and cofunded by the European Union through projects PI20/00645, PI23/00396, and FORT23/00023, and by the MCIN/AEI/10.13039/501100011033 and «Next Generation EU»/PRTR (project CNS2023-144144). We thank Rosalba Gestión (nursing homes of Sevilla La Nueva, Madrid, Spain). M.A. acknowledges support from the Medical University of Graz (Start Fund, Flagship Project VASC-HEALTH and the excellence cluster MetAGE), BioTechMed-Graz (Young Researcher Group), the Austrian Science Fund (FWF; DOI: https://doi.org/10.55776/P34926 & DOI: https://doi.org/10.55776/COE14), and the European Commission (H2020-MSCA-IF). M.A. and G.K. received funding from FWF (DOI: https://doi.org/10.55776/I6931) and ANR (Ener-LIGHT consortium) under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme. O.M. is supported by the “Beatriz Galindo Junior” Program from the Spanish Ministry of Universities (BG22/00104). Research by A.L. and C.F.L. is funded by Wereld Kanker Onderzoek Fonds as part of the World Cancer Research Fund International grant program (IIG_FULL_2021_007)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NGFR expression predicts tumor recurrence in radiotherapy/chemoradiotherapy-treated HPV-negative pharyngeal squamous cell carcinoma

  • García-Agulló, Juan
  • Santos, Vanesa
  • Garcia-Mayea, Yoelsis
  • de Luxan-Delgado, Beatriz
  • Bataller, Marina
  • Lleonart, Matilde Esther
  • Rodrigo, Juan P
  • García-Pedrero, Juana M
  • Álvarez-Fernández, Mónica
  • Peinado, Héctor
Supplementary data to this article can be found online at https://doi.org/10.1016/j.oraloncology.2026.108080, Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy with high mortality rates, often exhibiting resistance to conventional treatments such as radiotherapy (RT) or a combination of chemotherapy and radiotherapy (CRT). The nerve growth factor receptor (NGFR, also known as p75NTR or CD271) is a well-established cancer stem cell marker in melanoma, where it has been linked to resistance to multiple therapies. In HNSCC, NGFR has been reported as a poor prognostic marker, with its overexpression associated with disease progression. However, its contribution to therapy resistance in HNSCC remains unknown., Research in the laboratory of Dr Peinado is supported by grants from Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación / State Research Agencia Financiadora (AEI − Ministry of Science and Innovation: PID2020-118558RB-I00 (MICIU/AEI/https://doi.org/10.13039/501100011033), RETOS SAF2017-82924-R (AEI/https://doi.org/10.13039/501100011033/FEDER-UE), PDC2021-121102-I00 (MCIN/AEI/https://doi.org/10.13039/501100011033, European Union “NextGenerationEU”/PRTR), PID2023-147503OB-I00 funded by MCIU/AEI /https://doi.org/10.13039/501100011033 and by the European Union, ERDF “A way of making Europe”, Fundación Científica AECC (PRYCO223002PEIN, LABAE19027PEIN), the Mission Cancer within HORIZON EU Programme (PANCAID-101096309) and Fundación Ramón Areces. J.G.-A. was supported by Fundación Científica de la Asociación Española Contra el Cáncer (Predoctoral AECC 2021, PRDMA21602GARC). J.M.G.-P. and J.P.R. received funding from the Instituto de Salud Carlos III (ISCIII) through the project grants PI22/00167, PI25/00107 and CIBERONC (CB16/12/00390) and were co-funded by the European Union. J.M.G.-P. and J.P.R. are funded by the Government of the Principality of Asturias through the Agency for Science, Business Competitiveness and Innovation of the Principality of Asturias and co-financed by the European Union (IDE/2024/000778). M.A.-F. was supported by grant CNS2023-1444–73 funded by MCIU/AEI/https://doi.org/10.13039/501100011033 and “EuropeanUnionNextGenerationEU/PRTR” and by the Scientific Foundation of the Spanish Association against Cancer (LABAE235202ALVA). M.E. LL. received funding from the Instituto de Salud Carlos III (ISCIII) through the project grants PI24/00630 and AC24/00057, the latter under the umbrella of the Partnership Fostering a European Research Area for Health (ERA4Health) (GA N° 101095426 of the EU Horizon Europe Research and Innovation Programme)., Peer reviewed, Sin experimentacion animal ni uso de NAMs
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effects of ambient air pollutants and environmental greenness on the incidence of pre-/hypertension in children and adolescents

  • Wolters, Maike
  • Nagrani, Rajini
  • Naaouf, Nour
  • De Henauw, Stefaan
  • Lissner, Lauren
  • Moreno, Luis A
  • Molnár, Dénes
  • Russo, Paola
  • Vrijkotte, Tanja
  • Ahrens, Wolfgang
  • Börnhorst, Claudia
Aims This study estimates long-term effects of air pollution and greenness on the incidence of pre-/hypertension in children and adolescents. Methods and results Exposures to particulate matter <2.5 µm (PM2.5), black carbon (BC), and nitrogen dioxide (NO2) at the residential addresses of 2385 children and adolescents of the IDEFICS/I.Family cohort were estimated using land use regression models; environmental greenness was assessed using the Normalized Difference Vegetation Index (NDVI). Applying g-computation, we estimated the effects of hypothetical reductions of PM2.5, BC, NO2, and increases of NDVI on the incidence of pre-/hypertension over a 6-year period compared with no intervention. The observed risk of developing pre-/hypertension was 14.4%. We found a dose-dependent relationship showing higher risk reductions when imposing lower hypothetical levels or larger percental reductions for the air pollutants. The largest effects were observed for PM2.5, e.g. reducing PM2.5 to ≤10 μg/m3 lowered the risk of developing pre-/hypertension by −10.7 [−14.1, −5.7; 95% bootstrap CI] percentage points compared with no intervention. Effects of BC reductions were less strong, e.g. −5.3 [−10.2, 1.7] when reducing BC to ≤0.8 × 10−5/m and small (non-significant) effects were found for NO2. Hypothetically increasing NDVI to ≥0.6 lowered the pre-/hypertension risk by −1.5 [−2.9, −0.4]. Sensitivity analyses suggested effects of air pollution mainly on systolic (SBP) but not diastolic blood pressure. Conclusion Adherence to recommended levels of air pollutants and increased greenness can help to prevent hypertension among children and adolescents. Efforts to reduce air pollution could thus reduce the cardiovascular disease burden in later life.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Promoting active outdoor play and healthy dietary behaviours through the co-creation of supporting physical and social environments for and with primary school-aged children living in underserved neighbourhoods in Europe: the protocol of the B-Challenged project

  • Altenburg, Teatske M
  • Pawlowski, Charlotte S
  • Ahrens, Wolfgang
  • Brand, Tilman
  • Buck, Christoph
  • Börnhorst, Claudia
  • Dzielska, Anna
  • Klaufus, Leonie
  • Miguel-Etayo, Pilar de
  • Moreno, Luis
  • Okulicz-Kozaryn, Katarzyna
  • Vrijkotte, Tanja G M
  • Wink, Renée
  • Belmon, Laura S
  • Chinapaw, Mai J M
Introduction An alarmingly low number of children meet public health guidelines for physical activity and dietary behaviours and, therefore, are at increased risk of developing lifestyle-related diseases. This paper describes the protocol of the B-Challenged project, which aims to co-create systemic actions to promote active outdoor play and healthy dietary behaviours before, during or after their outdoor play together with children themselves. Methods and analysis In five European countries, child-centred Participatory Action Research (PAR)—combined with systems dynamics methods—was conducted with 15–20 child co-researchers (aged 9–12 years) and 15–20 adult actors (eg, youth workers, local policy makers). In the first phase, the main drivers of children’s active outdoor play and related dietary behaviours were mapped by (1) analysing existing cohort data, and (2) conducting child-centred PAR. In the second phase, systemic actions targeting the local physical and social environments will be co-created and implemented by child co-researchers and adult actors to promote children’s active outdoor play and related healthy dietary behaviours. A mixed-methods design will be used to evaluate (1) if actions positively contributed to systems change and 6- to 12-year-olds’ outdoor play and related dietary behaviours (140 children per country); (2) the process of conducting multi-actor, child-centred PAR and implementing the co-created actions and (3) if the child-centred PAR positively contributed to child co-researchers’ feelings of empowerment. Ethics and dissemination Ethics approval for the mapping phase was obtained and approval for implementation and evaluation will be obtained from the five local research institutions. Participating children, one of their parents/caregivers and adult actors had given informed consent before participating in the project. Throughout the project, child-friendly methods, materials and language will be applied, and ethical challenges and potential solutions will be discussed. Project results will be disseminated locally and internationally through various channels and activities among the scientific community, professionals—for example, in health and policy making, children and other citizens.